Pneumocystis Jirovecii Infection Clinical Trial
Official title:
Factors Associated With Survival in Patients With a Positive Sample for Pneumocystis Jirovecii at the Strasbourg University Hospital: a Retrospective Study From 2016 to 2018
Pneumocystis jirovecii is a fungus that can colonize the airways of some patients and be responsible for a disease called pneumocystosis in other patients and mainly in immunocompromised patients. Pneumocystosis was mainly linked to HIV in the 1990s, but with the advent of new immunosuppressive molecules used in cancers or autoimmune diseases and with the increase in the number of transplants, the epidemiology has changed in recent years. Studies on P. jirovecii-related mortality are only based on patients with pneumocystosis. As a result, patients who are simply colonized or patients who are sick but not treated are not taken into account in these studies. The investigators therefore wish to study the overall mortality at six weeks and at three months in all patients with a positive sample for P. jirovecii
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04851015 -
Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii Pneumonia
|
Phase 3 | |
| Recruiting |
NCT05707156 -
Prospective Observational Study on the Incidence of Opportunistic Fungal Infections
|
||
| Completed |
NCT05458752 -
Pneumocystis Jirovecii Pneumonia in Non-HIV-infected Immunocompromised Patients
|